Liver Cirrhosis Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Liver
Cirrhosis – Pipeline Review, H1 2019” drug pipelines has been
added to ResearchAndMarkets.com’s offering.

Liver Cirrhosis – Pipeline Review, H1 2019, provides comprehensive
information on the therapeutics under development for Liver Cirrhosis
(Gastrointestinal), complete with analysis by stage of development, drug
target, mechanism of action (MoA), route of administration (RoA) and
molecule type. The guide covers the descriptive pharmacological action
of the therapeutics, its complete research and development history and
latest news and press releases.

The Liver Cirrhosis (Gastrointestinal) pipeline guide also reviews of
key players involved in therapeutic development for Liver Cirrhosis and
features dormant and discontinued projects. The guide covers
therapeutics under Development by Companies /Universities /Institutes,
the molecules developed by Companies in Phase III, Phase II, Phase I,
Preclinical and Discovery stages are 1, 7, 1, 9 and 1 respectively.
Similarly, the Universities portfolio in Preclinical stages comprises 1
molecules, respectively.

Liver Cirrhosis (Gastrointestinal) pipeline guide helps in identifying
and tracking emerging players in the market and their portfolios,
enhances decision making capabilities and helps to create effective
counter strategies to gain competitive advantage.

Scope:

• The pipeline guide provides a snapshot of the global therapeutic
  landscape of Liver Cirrhosis (Gastrointestinal).
• The pipeline guide reviews pipeline therapeutics for Liver Cirrhosis
  (Gastrointestinal) by companies and universities/research institutes
  based on information derived from company and industry-specific
  sources.
• The pipeline guide covers pipeline products based on several stages of
  development ranging from pre-registration till discovery and
  undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline
  products which comprise, product description, descriptive licensing
  and collaboration details, R&D brief, MoA & other developmental
  activities.
• The pipeline guide reviews key companies involved in Liver Cirrhosis
  (Gastrointestinal) therapeutics and enlists all their major and minor
  projects.
• The pipeline guide evaluates Liver Cirrhosis (Gastrointestinal)
  therapeutics based on mechanism of action (MoA), drug target, route of
  administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued
  pipeline projects.
• The pipeline guide reviews latest news related to pipeline
  therapeutics for Liver Cirrhosis (Gastrointestinal)

Reasons to buy:

• Procure strategically important competitor information, analysis, and
  insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio
  and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under
  development for Liver Cirrhosis (Gastrointestinal).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of
  leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players
  and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding
  Liver Cirrhosis (Gastrointestinal) pipeline depth and focus of
  Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by
  identifying prospective partners with the most attractive projects to
  enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects
  and understand from the know-how what drove them from pipeline.

Companies Mentioned

• AlfaSigma SpA
• Bristol-Myers Squibb Co
• Galectin Therapeutics Inc
• Gilead Sciences Inc
• Grifols SA
• International Stem Cell Corp
• Mina Therapeutics Ltd
• Novartis AG
• Pharmicell Co Ltd
• Rohto Pharmaceutical Co Ltd
• VESSL Therapeutics Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/czbg97/liver_cirrhosis?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Liver
and Kidney Disorders Drugs